Global Blood Therapeutics Inc (NASDAQ:GBT) has been assigned a consensus rating of “Buy” from the eighteen ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $106.46.
GBT has been the subject of several recent research reports. Cantor Fitzgerald upped their price objective on Global Blood Therapeutics from $105.00 to $130.00 in a research note on Thursday, May 7th. ValuEngine raised Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd. Oppenheimer reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Global Blood Therapeutics in a research note on Monday, June 15th. Stifel Nicolaus initiated coverage on Global Blood Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $112.00 price objective for the company. Finally, Canaccord Genuity reaffirmed a “hold” rating on shares of Global Blood Therapeutics in a research note on Thursday, June 25th.
In other Global Blood Therapeutics news, Director Dawn Svoronos sold 2,544 shares of the firm’s stock in a transaction on Friday, June 19th. The stock was sold at an average price of $63.94, for a total transaction of $162,663.36. Following the transaction, the director now directly owns 4,800 shares in the company, valued at approximately $306,912. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tricia Borga Suvari sold 4,080 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $75.00, for a total value of $306,000.00. Following the transaction, the insider now owns 7,441 shares in the company, valued at $558,075. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,330 shares of company stock worth $6,120,196. 4.20% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of GBT. Point72 Hong Kong Ltd increased its position in shares of Global Blood Therapeutics by 3,290.9% during the 4th quarter. Point72 Hong Kong Ltd now owns 373 shares of the company’s stock valued at $30,000 after purchasing an additional 362 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Global Blood Therapeutics by 62.0% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 883 shares of the company’s stock valued at $45,000 after purchasing an additional 338 shares during the last quarter. Truvestments Capital LLC purchased a new stake in shares of Global Blood Therapeutics during the 1st quarter valued at $47,000. Advisor Group Inc. increased its position in shares of Global Blood Therapeutics by 36.6% during the 4th quarter. Advisor Group Inc. now owns 1,145 shares of the company’s stock valued at $91,000 after purchasing an additional 307 shares during the last quarter. Finally, Focused Wealth Management Inc increased its position in shares of Global Blood Therapeutics by 244.2% during the 1st quarter. Focused Wealth Management Inc now owns 1,175 shares of the company’s stock valued at $60,000 after purchasing an additional 1,990 shares during the last quarter.
GBT traded down $3.49 on Tuesday, hitting $63.01. 22,996 shares of the stock were exchanged, compared to its average volume of 1,108,349. Global Blood Therapeutics has a 12 month low of $39.95 and a 12 month high of $87.54. The business has a 50-day moving average of $68.15 and a two-hundred day moving average of $69.27. The company has a debt-to-equity ratio of 0.30, a current ratio of 9.07 and a quick ratio of 8.83. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -12.86 and a beta of 1.90.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($1.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.47) by $0.27. The firm had revenue of $14.12 million for the quarter, compared to the consensus estimate of $3.65 million. During the same period in the prior year, the company earned ($0.87) EPS. Equities research analysts expect that Global Blood Therapeutics will post -4.49 earnings per share for the current fiscal year.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Further Reading: Net Income
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.